OPEN ACCESS Freely available online

Journal of Medical & Surgical Pathology

Commentary

Clinical Applications of Extracellular Vesicles in COVID-19 Virus Infection

Paulima Ghomsy*

Department of Plastic Surgery, University of Helsinki Finland, Helsinki, Finland

DESCRIPTION

Exosomes are a subgroup of Extracellular Vesicles (EVs) that are lipid-bilayer coarctate entities. They're discharged by most cell varieties and gift in a very wide range of body fluids [1]. They were initial represented in ductless gland fluid and seminal plasma, and historically termed prostasomes to their origin in prostate animal tissue cells [2]. Biogenesis of exosomes starts with formation of endocytic vesicles at the cytomembrane of any cell through clathrin or non clathrin mediated endocytosis giving rise to living thing formation of early endosomes. These endosomes bear a maturation method that has associate interaction with the Golgi apparatus to become late endosomes. The bilayer membrane close late endosomes will successively be subjected to invaginations, forming intraluminal vesicles finishing what's known as Multi Vesicular Bodies (MVB) intracellularly. The MVB can fuse with the cytomembrane so as to unleash their content (intraluminal vesicles) by exocytosis. The secreted extracellular vesicles are termed exosomes. It ought to be noted that the exosomal membrane is unturned in regard to the cytomembrane thanks to the said double invaginations.

Membrane compound macromolecule, additionally called CD46 is related to the prostasome membrane [3]. CD46 could be a contagion virus receptor. The prostasomes were ready to neutralize contagion virus infectivity through membrane bound CD46. These authors additionally realized that soluble types of CD46 void of a membrane design were scarce for obstruction virus infection. An affordable interpretation for this finding was conferred that means that prostasomes perform sort of a mock cell by binding the virus and there upon rendering it unable to infect different cells. Hence, a task in antimicrobial defense was early ascertained being attributed to prostasomes/exosomes.

Exosomes discharged into the airways throughout respiratory disease viral infection are characterized. The exosomes modified dynamically in macromolecule composition over the course of infection with increasing expression of host proteins with notable anti-influenza activity and infectious agent proteins with potential to trigger host immune responses [4]. It absolutely was shown that attachment factors for respiratory disease virus, alpha 2,3 and alpha a pair of, 6-linked sialic acids were gift on the surface of airway exosomes. These exosomes had the power to neutralize respiratory disease virus, thereby preventing the virus from binding and getting into target cells.

The target for COVID-19 virus is that the angiotensin-converting protein a pair of (ACE2) receptor, preponderantly localized in respiratory organ alveoli cells and within the brush border of enteral enterocytes. It may well be anticipated that in analogy with unleash of exosomes into airways throughout respiratory disease viral infection, exosomes likewise would be found in airways of affected patients throughout COVID-19 viral infection. Such exosomes within the airways would likely carry the ACE2 receptor on their membrane surfaces (being unturned as mentioned above) equally to what's the case for his or her host alveoli cells, so restraining the infectious agent attack already within the airways.

Severe COVID-19 viral infection will induce a protein storm resulting in acute metabolic process distress syndrome and multiple organ failure. Mesenchymal vegetative cell therapies and, additional recently, their discharged exosomes are extremely regarded for his or her regenerative capacities. Additionally, they possess immunoregulatory functions poignant every type of innate and adaptive immune cells [5,6]. Therefore, these exosomes may well be helpful, alone or together with different therapeutic agents, in patients infected with COVID-19 virus. Since stem cells and thereupon their discharged exosomes do occur in current blood, it's urged that merely, plasma transfusions would be helpful for patients with COVID-19 viral infection thanks to presence of vegetative cell exosomes in plasma.

There is proof that viruses will use endocytic routes to enter clean cells and hijack the exosomal liquid body substance pathway for infection. What's additional, exosomes play a task in response against virus pathogens, and virus infected cells turn out exosomes that are necessary mediators of antiviral responses.

REFERENCES

1. Raposo G, Stoorvogel W. Extracellular vesicles: Microvesicles, and friends. J Cell Biol. 2013;200(4):373-383.

Correspondence to: Paulima Ghomsy, Department of Plastic Surgery, University of Helsinki Finland, Helsinki, Finland, E-mail: Paulimaghomsy45@gmail.com

Received: August 10, 2021; **Accepted**: August 24, 2021; **Published**: August 31, 2021

Citation: Ghomsy P (2021) Clinical Applications of Extracellular Vesicles in COVID-19 Virus Infection. J Med Surg Pathol. 6:220.

2. Ronquist G, Hedstrom M. Restoration of detergent-inactivated adenosine triphosphatase activity of human prostatic fluid with concanavalin. Bio Phy Acta. 1977;83:483-486.
3. Kitamura M, Namiki M, Matsumiya K, Tanaka K, Matsumoto M, Hara T, et al. Membrane cofactor protein (CD46) in seminal plasma is a prostasome-bound form with complement regulatory activity and measles virus neutralizing activity. Immunol. 1995;84:626-633.
4. Bedford JG, Infusini G, Dagley LF, Villalon F, Zheng MZM, Bennett-Wood V, et al. Airway exosomes released during influenza virus infection serve as a key component of the antiviral innate immune response. Front Immunol. 2020.
5. Randall HC, Jovicic N, Djonov V, Volarevic V. Therapeutic use of mesenchymal stem cell-derived exosomes: From basic science to clinics. Pharmaceut. 2020;12(5):E4-74.
6. Tsuchiya A, Takeuchi S, Iwasawa T, Kumagai M, Sato T, Motegi S et al. Therapeutic potential of mesenchymal stem cells and their exosomes in severe novel coronavirus disease 2019 (COVID-19) cases. Inflamm Regen. 2020;40:14-18.